Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Renown Pharmaceuticals Pvt Ltd

    Renown Pharmaceutical Pvt. Ltd. is into manufacturing and export of Soft gelatine capsules. was originally incorporated during September 2005 as Renown Ceratek Pvt. Ltd. With a

  • No Image
    Rhydburg Pharmaceuticals Ltd

    Rhydburg Pharmaceuticals Ltd was incorporated in 1987. It manufactures a wide range of pharmaceutical formulations in the form of tablets, capsules, syrups and lotions, and deal

  • No Image
    Richcore Lifesciences Pvt Ltd

    Richcore Lifesciences Pvt Ltd is a Karnataka-based company engaged in developing enzyme solutions for cleantech and biopharma applications. The company plans to acquire its grou